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Abstract 
Background 
Inheritance of the F variant of alpha-1-antitrypsin is associated with normal circulating 
protein levels, but it is believed to be dysfunctional in its ability to inhibit neutrophil elastase 
and therefore has been implicated as a susceptibility factor for the development of 
emphysema. In this study, its functional characteristics were determined following the 
identification of a unique patient with the PiFF phenotype, and the implications as a 
susceptibility factor for emphysema are considered both in homozygotes and heterozygotes. 
Methods 
Second order association rate constants were measured for M, Z, S and F variants of alpha-1-
antitrypsin with neutrophil elastase and proteinase 3. Clinical characteristics of the PiFF 
homozygote and six PiFZ heterozygote subjects were studied. 
Results 
The F variant had a reduced association rate constant with neutrophil elastase (5.60 ± 
0.83×106 M−1 s−1) compared to the normal M variant (1.45 ± 0.02×107 M−1 s−1), indicating an 
increased time to inhibition that was comparable to that of the Z variant (7.34 ± 0.03×106 M−1 
s−1). The association rate constant for the F variant and proteinase 3 (1.06 ± 0.22×106 M−1 s−1) 
was reduced compared to that with neutrophil elastase, but was similar to that of other alpha-
1-antitrypsin variants. Of the six PiFZ heterozygotes, five had airflow obstruction and 
radiological evidence of emphysema. The PiFF homozygote had airflow obstruction but no 
emphysema. None of the patients had clinical evidence of liver disease. 
Conclusions 
The F variant may increase susceptibility to elastase-induced lung damage but not 
emphysema, whereas co-inheritance with the Z deficiency allele may predispose to 
emphysema despite reasonable plasma concentrations of alpha-1-antitrypsin. 
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Background 
Alpha-1-antitrypsin deficiency (A1ATD) is a recognised genetic condition that predisposes to 
the development of early onset basal panacinar emphysema [1]. The pathophysiology is 
thought to reflect a critically low or absent level of alpha-1-antitrypsin (A1AT) which 
reduces the ability of the lung to protect itself from neutrophil serine proteinases (NSPs) such 
as neutrophil elastase (NE) and proteinase 3 (PR3) [2]. The ability of A1AT to protect tissues 
is both dependant on its concentration and also the speed with which it traps and inactivates 
these enzymes, its association rate constant (Kass). The third NSP inhibited by A1AT, 
cathepsin G, does not produce emphysema-like lesions in animal models, and has not been 
included in this study. 
The F variant of A1AT was first described in 1965 [3] and results from a single amino acid 
substitution of arginine at residue 223 by cysteine [4]. It has been reported to have a low Kass 
for NE [5], and has thus been implicated as a susceptibility factor for emphysema in its own 
right despite normal serum and hence lung levels. The F variant is relatively uncommon 
(reported to have an allelic frequency of approximately 0.002 in the Caucasian population 
[4]) making clinical and epidemiological studies impractical. Even cases of heterozygotes 
with the Z or other deficiency variants which have both low A1AT levels and reduced Kass 
for NE are infrequent [6-9], although such patients are often considered for augmentation 
therapy. 
We report a unique case of a patient who is homozygous for the F variant that permitted us to 
measure the Kass for NE and PR3 with confidence and also review the clinical features both 
of this patient and of those heterozygous with the Z variant. These data provide insight into 
whether the F variant represents a risk factor for the development of emphysema, either alone 
or in combination with the Z variant. 
Methods 
Subject selection 
Subjects with A1ATD including PiZZ and PiSS homozygotes and six PiFZ heterozygotes 
were identified from the U.K. A1ATD national registry (based at Queen Elizabeth Hospital, 
Birmingham, U.K.) with a confirmed diagnosis by phenotyping and genotyping (Heredilab, 
Salt Lake City, Utah, USA). One PiFF homozygote was identified from the Kentucky Lung 
Clinic (Hazard, Kentucky, USA) with a confirmed diagnosis by phenotyping (isoelectric 
focusing, University of Florida laboratories, Florida, USA). All subjects had demographic 
data recorded including; medical history, clinical examination, smoking history, quality of 
life measures (St George’s Respiratory Questionnaire, SGRQ), pulmonary function tests 
(PFTs), computed tomography (CT) of the thorax, and routine clinical biochemical and 
haematological parameters. Healthy controls were partners of patients with A1ATD and had 
a normal PiMM A1AT phenotype. All subjects provided written informed consent for this 
study, and ethical approval was obtained for this project (South Birmingham Research Ethics 
Committee LREC 3359). 
Sample collection 
Venous blood was collected from all subjects, and serum was obtained using Vacuette® 
serum tubes (Greiner bio-one, UK) following clot formation. The tubes were centrifuged at 
1800 × g for ten minutes at room temperature, and serum was harvested and stored in 
multiple aliquots at −70°C until analysed, to minimise freeze-thaw cycles. 
Active site titration of enzymes 
Pure PR3 (Merck, Feltham, UK) and pure NE (Athens Research and Technology, Athens, 
Georgia, USA) were active site titrated against pure M variant A1AT (Athens Research and 
Technology, USA), which had itself been previously titrated against porcine pancreatic 
elastase (PPE; Sigma-Aldrich, Gillingham, UK). The activity of PPE was determined using 
Lineweaver–Burk double-reciprocal plot analysis with N-succinyl-Ala-Ala-Ala-p-nitroanilide 
(SlaaapN; Sigma-Aldrich, UK) as the substrate and published kinetic constants [10]. 
Treatment of serum with methylamine to inactivate A2M 
In order to measure Kass for serum A1AT with NE or PR3, it was first necessary to inactivate 
the other major serum inhibitor of NSPs, alpha-2-macroglobulin (A2M). This was achieved 
by treating the serum samples with 0.1 M methylamine (Fisher Scientific, UK) for 10 minutes 
at 37°C [11]. The inactivation of A2M was confirmed indirectly by measuring NE and PR3 
inhibition by serum samples with and without treatment with methylamine. The substrate 
used for these experiments was N-Methoxysuccinyl-Ala-Ala-Pro-Val p-nitroanilide 
(MSaapvN; Sigma-Aldrich, UK) at 0.6 mg/ml in 0.1 M Hepes, pH 7.5, 9.5% dimethyl 
sulfoxide (DMSO). 
Measurement of Kass for A1AT variants and NE 
Pure NE of known activity was diluted to an active concentration of 100nM with buffer (50 
mM Hepes, pH 7.4, 150 mM NaCl, 0.05% Igepal CA-630 (v/v)). Methylamine-treated serum 
samples or pure M or Z variant A1AT were also diluted to an A1AT concentration of 100nM 
(Z variant A1AT purified from human plasma was a kind gift from the research group of 
Prof. D. Lomas, University of Cambridge, UK), and these samples were titrated against NE 
to determine the percentage of active A1AT. Following this initial step, the time-dependent 
measurements were performed by incubating equimolar amounts of NE and active A1AT 
(1nM each) in a 1 ml polystyrene cuvette with a 1 cm pathlength at 23°C. Residual NE 
activity at 1–5 minutes was measured by the addition of 200 µL of MSaapvN and 
measurement of the change in absorbance (410 nm) over 10 minutes using a 
spectrophotometer (Jasco V550). At each time point, the percentage of NE inhibition was 
determined. The Kass was calculated by plotting the inverse of NE activity at each time point 
versus time. From the linear portion of the slope, the half time (t½) of the reaction was 
calculated using the formula; 
t½    y intercept/slope 
Kass was calculated using the equation [12]; 
K  Concentration of NE  t½
-
 
Measurement of Kass for A1AT variants and PR3 
Pure PR3 of known activity was diluted to an active concentration of 400nM. Methylamine-
treated serum samples or purified M or Z variant A1AT were also diluted to an A1AT 
concentration of 400nM and were titrated against PR3 to determine the percentage of active 
A1AT. Following this initial step, the time-dependent measurements were performed by 
incubating equimolar amounts of PR3 and active A1AT (1nM each) in a black opaque 
polypropylene low binding plate (Sigma, UK) at 23°C with a well volume of 150 µL. 
Residual PR3 activity at 1–5 minutes was measured by adding 3 µL of the PR3 specific 
Förster resonance energy transfer (FRET) substrate Abz-VAD-norV-ADRQ-EDDnp (Alta 
Biosciences, UK) at a concentration of 1 mM [13]. The change in fluorescence (excitation 
320 nm, emission 420 nm) was measured every 2 minutes for 20 minutes using a Biotek 
Synergy 2 Multi-Mode Microplate Reader. At each time point, the percentage of PR3 
inhibition was determined. The Kass was calculated using the same method as that for NE. 
Results 
Association rate constants for A1AT variants and NSPs 
The second order association rate constant (Kass) values for different variants of A1AT with 
NE or PR3 are shown in Table 1. The F variant of A1AT has a reduced Kass value with NE 
compared to the normal M variant, suggesting that the speed with which it is able to 
inactivate NE is reduced, and comparable to that observed with the Z variant. The Kass values 
for A1AT variants and PR3 are reduced compared to those with NE, indicating that NE 
would be preferentially inhibited in circumstances where the local concentration of A1AT is 
insufficient to inhibit both NSPs. The results obtained using purified M or Z variant A1AT 
were comparable to those obtained using methylamine-treated sera (1.47 × 107 M−1 s−1 for 
NE and 9.83 × 105 M−1 s−1 for PR3 with pure M variant A1AT, and 7.39 × 106 M−1 s−1 for NE 
and 1.03 × 106 M−1 s−1 for PR3 with pure Z variant A1AT). 
Table 1 Kass values for A1AT variants and NE or PR3 
A1AT variant Association rate constant with NE Association rate constant with PR3 
(Mean ± SEM) at 23°C (M−1 s−1) (Mean ± SEM) at 23°C (M−1 s−1) 
M (1.45 ± 0.02) × 107 (9.24 ± 0.48) × 105 
S (1.14 ± 0.36) × 107 (9.51 ± 3.00) × 105 
Z (7.34 ± 0.03) × 106 (1.10 ± 0.21) × 106 
F (5.60 ± 0.83) × 106 (1.06 ± 0.22) × 106 
Clinical characteristics of PiFZ heterozygotes 
The clinical characteristics of the six PiFZ heterozygote subjects identified from the U.K. 
A1ATD national registry are summarised in Table 2. All subjects had A1AT concentrations 
above the putative “protective threshold” of 11 µM and were ex-smokers. Five of the subjects 
had airflow obstruction on spirometry, as defined by a post-bronchodilator FEV1/FVC ratio 
<0.7, and these subjects also had radiological evidence of emphysema on high resolution CT 
(HRCT) scanning, which was panacinar with a lower zone predominance (consistent with the 
classical distribution and type in PiZZ homozygotes) in two and upper zone predominant in 
two. The remaining patient had widespread emphysema with no dominant distribution. None 
of the subjects had biochemical evidence of liver disease, with liver enzymes within the 
normal range for all subjects. 
Table 2 Clinical characteristics of six PiFZ heterozygotes identified in the UK 
Clinical 
Parameter 
Patient 1 Patient 
2 
Patient 3 Patient 4 Patient 5 Patient 6 
Age (years) 59 47 70 74 76 53 
Sex M M F M M M 
A1AT 
concentration 
(µM) 
18.7 21.6 24.0 11.8 18.3 19.7 
Smoking history 
(pack years) 
24 24 23 19 8 40 
BMI (kg/m2) 23 33 19 29 29 20 
FEV1 (% 
predicted) 
29 110 33 99 32 38 
FEV1/FVC ratio 0.22 0.77 0.32 0.55 0.31 0.21 
KCO (% 
predicted) 
26 100 57 63 87 40 
PO2 on air (kPa, 
capillary blood 
gas) 
7.3 8.8 7.8 9.3 7.8 8.8 
Average number 
of exacerbations 
per year 
2 0 2 2 4 1 
SGRQ (total 
score) 
63 20 75 42 68 26 
CT scan 
appearance 
Upper zone 
emphysema 
Normal Diffuse 
emphysema in 
all zones 
Basal 
emphysema 
Basal 
emphysema & 
bronchiectasis 
Diffuse 
emphysema, 
upper zone 
predominant 
Case report of a PiFF homozygote 
A 75 year old caucasian gentleman initially presented to the respiratory clinic in 2004 with a 
history of increasing exertional dyspnoea over several years and occasional cough productive 
of green sputum. He was diagnosed with chronic obstructive pulmonary disease (COPD) by 
spirometry in 2004, but subsequently attended for follow-up only sporadically. He reported 
having on average 3 pulmonary exacerbations per year. His serial spirometry values are 
shown in Table 3, with the most recent values showing an obstructive defect, with a pre-
bronchodilator FEV1 of 0.75 L (23% predicted), FVC 1.70 L (41% predicted) and 
FEV1/FVC 44%. His current gas transfer is however within normal limits with DLCO 16.6 
mL/mmHg/min (81% predicted) and KCO 2.93 mL/mmHg/min/L (87% predicted). His 
arterial blood gases (on room air) show pO2 10.1kPa, pCO2 5.2kPa and pH 7.46. 
Table 3 Serial spirometry from a PiFF homozygote 
Date Pre-bronchodilator 
FEV1 L (%) 
Pre-bronchodilator 
FVC L (%) 
Pre-bronchodilator 
FEV1/FVC 
Post-bronchodilator 
FEV1 L (%) 
Post-bronchodilator 
FVC L (%) 
Post-bronchodilator 
FEV1/FVC 
Oct 
2004 
0.74 (21.0%) 1.65 (37.2%) 44.8 1.05 (29.8%) 2.34 (52.7%) 44.9 
July 
2005 
1.15 (32.6%) 2.14 (48.2%) 53.6 1.24 (35.3%) 2.24 (50.5%) 55.4 
May 
2007 
0.86 (24.9%) 1.93 (44.1%) 44.6 0.97 (28.0%) 2.07 (47.4%) 46.7 
Dec 
2008 
1.04 (33.8%) 2.28 (58.4%) 45.5 Not performed Not performed Not performed 
Aug 
2009 
0.96 (28.3%) 2.51 (58.1%) 38.4 1.10 (32.5%) 2.69 (62.3%) 41.0 
April 
2012 
0.74 (22.4%) 1.58 (37.4%) 47.0 Not performed Not performed Not performed 
Jan 
2013 
0.75 (23%) 1.70 (41%) 44.1 Not performed Not performed Not performed 
He has a past medical history of hypertension, hyperlipidaemia, coronary artery disease, 
pacemaker for second degree heart block and bradycardia, restless legs syndrome and left 
renal calculus. He has no history of liver disease. His medication consists of salbutamol PRN, 
fluticasone/salmeterol 500mcg/50mcg bd, montelukast 10 mg od, roflumilast 500 µg od, 
carbidopa/levodopa 10/100 mg tds, omeprazole 20 mg od, metoprolol 50 mg bd, 
hydrochlorothiazide 12.5 mg od, rosuvastatin 5 mg od, aspirin 81 mg od, and home oxygen 
therapy for 18–20 hours per day for 4 years. 
He is an ex-smoker having stopped 15 years previously, with a 100 pack year smoking 
history. There is no history of excessive alcohol intake or illicit drug use. He is retired, but 
previous occupations include working in school maintenance, as a bus driver, strip coal 
mining for 4–5 years, and as a carpenter for 20 years. His father had asthma and “bronchitis” 
and was a lifelong non-smoker. His mother was also a non-smoker and had no respiratory 
problems. He has no siblings and has 3 children who are healthy and 2 grandchildren, one of 
whom has asthma but a normal PiM phenotype. 
On physical examination, his body mass index (BMI) was 25.8 kg/m2. He had an oxygen 
saturation of 96% on room air, and clear lungs on auscultation with good bilateral air entry. 
Cardiovascular examination was normal and there was no peripheral oedema, cyanosis or 
finger clubbing. 
His A1AT concentration was 37.7 µM by nephelometry and phenotype PiFF by isoelectric 
focusing. Routine haematological parameters and hepatic and renal function tests were within 
normal limits. His SGRQ total score was 73. 
A HRCT scan of the thorax performed in 2013 showed fibrosis and pleural thickening at the 
apices and bronchial wall thickening around the hilum, but no radiological evidence of 
emphysema or bronchiectasis (as shown in Figure 1). An echocardiogram showed a left 
ventricular ejection fraction of 55-60%, and normal right ventricular function with no 
evidence of pulmonary hypertension. 
Figure 1 HRCT thorax of the PiFF homozygote. There is no radiological evidence of 
emphysema or bronchiectasis. 
Discussion 
We have used the unique identification of a patient with the PiFF phenotype of A1ATD to 
ascertain the function of F variant A1AT, and consider whether its inheritance represents a 
susceptibility factor for developing emphysema, in either the homozygous or heterozygous 
state. The F variant of A1AT has generally been thought not to be clinically important 
because of its near normal circulating levels [14]. However, previous reports have suggested 
that the F variant has abnormal function, and may therefore predispose to the development of 
lung or liver disease (typical of the Z variant) when co-inherited with another deficiency gene 
as in the PiFZ heterozygote. In 1974, Brand et al. [15] reported a case of liver cirrhosis in a 
PiFZ heterozygote, although the subject had no evidence of emphysema. Subsequently in 
1981, Cockcroft et al. [6] reported 3 PiFZ siblings who all had moderate to severe COPD, 
two of whom had radiological evidence of emphysema. Their six living siblings (3 PiFM, 2 
PiMM and 1 PiMZ) had milder abnormalities in pulmonary function despite similar smoking 
histories and exposure to grain dust suggesting that the FZ combination was a susceptibility 
factor. In 1982, Billingsley and Cox [14] reported that PiFM serum showed reduced specific 
activity with elastase (PPE) compared to the normal PiMM variant. Subsequently, Beckman 
et al. [7] in 1984 reported that in 13 individuals heterozygous for the F variant of A1AT, 
respiratory symptoms were present in seven out of twelve PiFM heterozygotes, of whom five 
had abnormal PFTs, and one PiFZ heterozygote who had bronchitic symptoms and mild 
airflow obstruction on spirometry. They hypothesized that an increased risk for pulmonary 
disease may be due to dysfunction of the F protein, independent of the A1AT concentration. 
A case report by Kelly et al. [8] described a 56 year old PiFZ lady with a 10 pack year 
smoking history and minimal alcohol intake who presented with advanced emphysema, cor 
pulmonale and abnormalities on liver biopsy consistent with A1ATD. More recently, a 64 
year old male with the PiFnull phenotype has been reported [9]. This patient had a 10 pack 
year smoking history and moderate COPD, with no biochemical evidence of liver disease. 
This patient was commenced on A1AT augmentation therapy with no further decline in lung 
function or symptoms reported. 
The cases described in the present study demonstrate that five of the six unrelated PiFZ 
heterozygotes identified from the U.K. A1ATD national registry had COPD with radiological 
evidence of emphysema, although none had biochemical evidence of liver disease. The 
A1AT levels were within the “normal” range and consistent with those of PiMZ 
heterozygotes [16] although only two had the classical basal distribution of emphysema 
typical of PiZZ homozygotes. Whether this level of A1AT predisposes to the development of 
COPD however, remains uncertain. The patients were referred to the U.K. registry because of 
the identification of the PiFZ phenotype and may therefore reflect an acquisition bias. The 
PiMZ heterozygous state has long been studied as a potential risk factor and a meta-analysis 
does suggest a slight increase in susceptibility [17], with the heterozygous state being 
associated with more hospitalisations [18] and a more severe form of COPD [19,20]. An 
additional risk might be conferred by the proposed reduction in Kass for NE by the F protein. 
The PiFF homozygote reported here enabled us to confirm the reduction in Kass with 
confidence, but despite this and a significant smoking history, the patient did not have 
radiological evidence of emphysema or impaired transfer factor, although he did have 
significant physiological impairment on spirometry. His A1AT concentration was within the 
normal range of PiMM homozygotes [16]. The absence of emphysema despite a significant 
smoking history suggests that homozygosity for the F variant is not a significant risk factor 
for the development of emphysema. It remains possible, however, that co-inheritance of the F 
variant of A1AT with another deficiency allele does increase the risk of developing 
emphysema, although the distribution in the PiFZ patients reported here is more consistent 
with usual COPD and PiSZ heterozygotes [21] than PiZZ homozygotes, suggesting a 
different mechanism. In PiMZ heterozygotes, the increased susceptibility to developing 
COPD is accentuated in ever-smokers [20]. It could therefore be postulated that cigarette 
smoking in PiFZ heterozygotes could lead to a more severe form of COPD than in PiMZ 
heterozygotes due to the reduced Kass for NE by the F protein. Whether A1AT augmentation 
therapy should be considered for PiFZ heterozygotes remains unknown since the A1AT 
concentration is low and both the F and Z variants have reduced Kass for NE. 
Our cases have not demonstrated any association between the F variant of A1AT and liver 
disease, although case reports have been described elsewhere in PiFZ heterozygotes [8,15]. 
The loop sheet polymers formed by the Z protein are retained within the rough endoplasmic 
reticulum of hepatocytes forming periodic acid Schiff (PAS) positive hepatic inclusions [22], 
and this accumulation can lead to liver disease including hepatitis, cirrhosis and 
hepatocellular carcinoma [23] in PiZZ homozygotes. Co-inheritance of the Z variant as a 
heterozygote will still form polymers and even heteropolymers [24], and although the 
susceptibility of the F variant to polymerise has not been reported in the literature to date, it 
remains a possible mechanism whereby some PiFZ heterozygotes may be at increased risk of 
developing liver disease. 
In future studies, it would be ideal to use purified F variant A1AT to measure Kass values with 
the NSPs. However, the results presented here using purified M or Z variant A1AT were 
comparable to those obtained using methylamine-treated sera, supporting the use of this 
method for the F variant of A1AT. In addition, our results are consistent with those reported 
elsewhere by Cook et al. [5], who used partially purified F variant A1AT. 
A potential mechanism for the impaired function of the F variant may relate to the position of 
the mutation (arginine replaced by cysteine at position 223). Examination of the structure of 
A1AT shows that the mutation is in the C-sheet underlying the reactive centre loop (RCL). 
With the normal M variant, an arginine at position 223 forms an electrostatic interaction with 
the side chain of glutamate 354 in the RCL [25]. However, with the F variant, the cysteine at 
position 223 cannot make this electrostatic interaction and the consequence is likely to be a 
disruption of the RCL architecture which alters the conformation of the P1-P1’ region (the 
bond cleaved by target NSPs) and may explain the reduced Kass with NE observed here. 
The data presented here also confirms that F A1AT has a similar Kass for PR3 to that of the 
normal M variant, suggesting a less significant effect of mutations in A1AT on its ability to 
inhibit PR3. Therefore, inhibition of PR3 activity is likely to be more dependent on local 
A1AT concentrations than Kass. Previous studies have suggested that PR3 activity is inhibited 
only when NE has been totally inhibited [26], and therefore in situations where there is 
insufficient A1AT to inhibit both NSPs, NE will be preferentially inhibited. PR3 can replicate 
the pathological features of COPD associated classically with NE and should be considered 
when evaluating the proteinase/anti-proteinase imbalance observed in A1ATD [27], as its 
activity is likely to persist longer in the lung in the presence of neutrophilic inflammation. 
Whether the reduced A1AT concentration in PiFZ heterozygotes and the reduced Kass for NE 
alters this relationship remains to be determined. 
Conclusion 
We have demonstrated that the F variant of A1AT has a reduced functional ability to inhibit 
NE (but not PR3) compared to the normal M variant. This may be of clinical significance 
when the F variant is co-inherited with the Z variant or another deficiency variant, although 
its significance is less certain in the homozygous state when concentrations of A1AT are 
normal. 
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